Corey Gilliland, DO
General Practice · Anniston, ALNPI 1043335136
Payments from drug & device makers
Across 118 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$468
- Orexo US, Inc.$204
- Assertio Therapeutics, Inc.$180
- Indivior Inc.$129
- Daiichi Sankyo Inc.$104
- Collegium Pharmaceutical, Inc.$96
- plus $685 from 18 others
What the payments were for
- Food & beverage$1,864100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 27 | $468 |
| Orexo US, Inc. | 10 | $204 |
| Assertio Therapeutics, Inc. | 16 | $180 |
| Indivior Inc. | 13 | $129 |
| Daiichi Sankyo Inc. | 5 | $104 |
| Collegium Pharmaceutical, Inc. | 6 | $96 |
| Biodelivery Sciences International, Inc. | 5 | $85 |
| AbbVie(2 entities) | 4 | $61 |
| Medtronic(2 entities) | 3 | $55 |
| Redhill Biopharma Inc. | 3 | $55 |
| Hikma Pharmaceuticals USA | 3 | $53 |
| AstraZeneca | 3 | $51 |
| Almatica Pharma LLC | 3 | $48 |
| Abbott | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| MDD US Operations, LLC | 2 | $28 |
| Scilex Pharmaceuticals Inc. | 2 | $27 |
| Si-bone, Inc. | 2 | $26 |
| Amgen | 1 | $23 |
| Shionogi Inc | 1 | $22 |
| Braeburn Inc. | 1 | $20 |
| Pfizer | 1 | $11 |
| Zyla Life Sciences, Inc. | 1 | $11 |
How this compares
$1,865 in reported general payments places this provider in the 85th percentile of 1,114 general practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 376 | $98,219 |
| BelbucaBuprenorphine Hcl | 118 | $88,090 |
| Xtampza ErOxycodone Myristate | 130 | $67,369 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 243 | $40,416 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 57 | $30,662 |
| LinzessLinaclotide | 56 | $28,074 |
| Hysingla ErHydrocodone Bitartrate | 39 | $24,488 |
| MovantikNaloxegol Oxalate | 57 | $22,347 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,095 | $19,518 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 977 | $16,825 |
| UbrelvyUbrogepant | 12 | $12,293 |
| OxycontinOxycodone Hcl | 30 | $12,118 |
| Gabapentin | 1,322 | $11,701 |
| Morphine Sulfate ErMorphine Sulfate | 424 | $9,803 |
| SymproicNaldemedine Tosylate | 15 | $6,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $96 | $155,459248 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl | $53 | $139,823631 claims |
| AbbVieLinzess, Ubrelvy | $61 | $40,36768 claims |
| Orexo US, Inc.Zubsolv | $204 | $30,66257 claims |
| Redhill Biopharma Inc.Movantik | $55 | $22,34757 claims |
| Shionogi IncSymproic | $22 | $6,52015 claims |
| Indivior Inc.Suboxone | $129 | $4,61714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,114 general practice providers in Alabama.
Other general practice in Anniston
- Morgan GibsonAnniston$3K
- Glenn HarnettHoover$4.5M
- Herrera DaniloMobile$716K
- John BurgessBirmingham$212K
- Frank TombrelloBirmingham$163K
- Bradley WillisMontgomery$151K
- Ashley McIntyreMontgomery$123K
- Scott BoswellJasper$111K
- Gregory FunkGulf Shores$42K
- Toni NeumeierBirmingham$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.